Research HER
Related Resources for this page:
- Future Directions
- Antibody-Drug Conjugates
- A brief history of ADCs
- Current research in ADCs
- Cytotoxic agent
- Emerging therapeutic options
- Emerging therapeutic options
- HER Signaling
- How are ADCs designed to work?
- Glossary
- Monoclonal antibody
- Research ADCs
- Slide decks and videos
- Stable linker
- Targeting cancers with ADCs
- Trastuzumab Emtansine (T-DM1)
- What are ADCs?
- Antibody-Drug conjugates
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Targeted Small Molecules
- Traditional Monoclonal Antibodies
- Antibody-Drug Conjugates
Share
Summary:HER3 in Cancer
HER3 is a key component of HER2–mediated tumorigenesis
- HER3 is a requirement for HER2 signaling in cancer2
- HER3 enables HER2 signaling by dimerizing with HER2
- Effects of HER2:HER3 signaling include:
- Activation of the PI3K signaling pathway2
- Escape from HER2 inhibition6
HER3 represents a potential therapeutic target
- Methods of targeting could include:
- Targeting HER2:HER3 dimerization22
- Targeting HER3 ligands
- Targeting downstream signaling pathways2
Additional clinical research is needed to better clarify the role of HER3 in cancer.